Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.
HPS3/TIMI55–REVEAL Collaborative Group; Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. HPS3/TIMI55–REVEAL Collaborative Group, et al. Among authors: collins r. N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28. N Engl J Med. 2017. PMID: 28847206 Free article. Clinical Trial.
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns HS, Collins R, Foley RN, Frighi V, Kourellias K, Ratcliffe PJ, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC. Baigent C, et al. Among authors: collins r. Am J Kidney Dis. 2005 Mar;45(3):473-84. doi: 10.1053/j.ajkd.2004.11.015. Am J Kidney Dis. 2005. PMID: 15754269 Clinical Trial.
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, Ball S, Baxter A, Blackwell L, Cairns HS, Carr S, Collins R, Kourellias K, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC. Landray M, et al. Among authors: collins r. Am J Kidney Dis. 2006 Mar;47(3):385-95. doi: 10.1053/j.ajkd.2005.11.018. Am J Kidney Dis. 2006. PMID: 16490616 Clinical Trial.
N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
Heart Protection Study Collaborative Group; Emberson JR, Ng LL, Armitage J, Bowman L, Parish S, Collins R. Heart Protection Study Collaborative Group, et al. Among authors: collins r. J Am Coll Cardiol. 2007 Jan 23;49(3):311-9. doi: 10.1016/j.jacc.2006.08.052. J Am Coll Cardiol. 2007. PMID: 17239712 Free article. Clinical Trial.
SLCO1B1 variants and statin-induced myopathy--a genomewide study.
SEARCH Collaborative Group; Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SEARCH Collaborative Group, et al. Among authors: collins r. N Engl J Med. 2008 Aug 21;359(8):789-99. doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23. N Engl J Med. 2008. PMID: 18650507 Free article. Clinical Trial.
Analyses of cancer data from three ezetimibe trials.
Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R. Peto R, et al. Among authors: collins r. N Engl J Med. 2008 Sep 25;359(13):1357-66. doi: 10.1056/NEJMsa0806603. Epub 2008 Sep 2. N Engl J Med. 2008. PMID: 18765432 Free article.
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
MRC/BHF Heart Protection Study Collaborative Group; Armitage J, Bowman L, Collins R, Parish S, Tobert J. MRC/BHF Heart Protection Study Collaborative Group, et al. Among authors: collins r. BMC Clin Pharmacol. 2009 Mar 31;9:6. doi: 10.1186/1472-6904-9-6. BMC Clin Pharmacol. 2009. PMID: 19442259 Free PMC article. Clinical Trial.
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Antithrombotic Trialists' (ATT) Collaboration; Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Antithrombotic Trialists' (ATT) Collaboration, et al. Among authors: collins r. Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1. Lancet. 2009. PMID: 19482214 Free PMC article.
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease.
Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown IJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Mooser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Elliott P, et al. Among authors: collins r. JAMA. 2009 Jul 1;302(1):37-48. doi: 10.1001/jama.2009.954. JAMA. 2009. PMID: 19567438 Free PMC article.
3,216 results